Opthea to Present at Oppenheimer Healthcare Conference

Rhea-AI Summary

Opthea (ASX/NASDAQ:OPT), a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases including wet age-related macular degeneration (wet AMD), has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference.

The company's Chief Executive Officer, Frederic Guerard, PharmD, will deliver a presentation on Tuesday, February 11, 2025, at 10:00 AM ET and will be available for one-on-one meetings during the conference, which runs from February 11-12, 2025. The presentation will be accessible via webcast and will also be available on the company's investor relations website.

MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at Oppenheimer’s 35^th Annual Healthcare Life Sciences Conference and host one-one-one meetings.

Details are as follows:

Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
Date:	February 11-12, 2025
Presentation:	Tuesday, February 11, 2025, 10:00 AM ET
Webcast Link:	https://wsw.com/webcast/oppenheimer39/opt/2588856
The webcast will also be accessible on the “Events & Presentations” section of the Company’s website at http://ir.opthea.com/.

About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age‐related macular degeneration (wet AMD) and diabetic macular edema (DME), which remain leading causes of vision loss worldwide.

Opthea’s lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C/D ‘trap’ inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients. Sozinibercept has the potential to become the first therapy in 20 years to enable patients with wet AMD live fuller and healthier lives.

To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.

Authorized for release to ASX by Frederic Guerard, PharmD, CEO

Investor Inquiries PJ Kelleher LifeSci Advisors, LLC Email:pkelleher@lifesciadvisors.com Phone: 617-430-7579	Media Inquiries Silvana Guerci-Lena NorthStream Global Partners Email:silvana@nsgpllc.com

Join our email database to receive program updates:  
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com   

Source: Opthea Limited

FAQ

When is Opthea (OPT) presenting at the Oppenheimer Healthcare Conference 2025?

Opthea (OPT) is scheduled to present on Tuesday, February 11, 2025, at 10:00 AM ET during Oppenheimer's 35th Annual Healthcare Life Sciences Conference.

How can investors watch Opthea's (OPT) Oppenheimer conference presentation?

Investors can watch the presentation through the webcast link provided or access it through the 'Events & Presentations' section of Opthea's website at ir.opthea.com.

What is the main focus of Opthea's (OPT) drug development program?

Opthea is developing novel therapies to treat highly prevalent and progressive retinal diseases, with a focus on wet age-related macular degeneration (wet AMD).

Will Opthea (OPT) offer one-on-one meetings during the Oppenheimer conference?

Yes, Opthea's CEO Frederic Guerard will be available for one-on-one meetings during the conference, which runs from February 11-12, 2025.